Lip, Oral Cavity and Pharynx, Phase I

A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer

Volunteers
Health Professionals

What is the purpose of this trial?

This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.

Trial with
Toragen, Inc.
Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Anna Wu

anna.wu@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Aarti Bhatia, MD, MPH
Associate Professor of Medicine (Medical Oncology); Clinical Research Team Leader, Head and Neck Cancers Program

Sub-Investigators

Last Updated
12/13/2024
Study HIC
#2000036416